换一批MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
第一作者：
Zijun Y,Xu-Monette
第一单位：
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;
作者：
医学主题词
成年人(Adult);老年人(Aged);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);环磷酰胺(Cyclophosphamide);多柔比星(Doxorubicin);女(雌)性(Female);随访研究(Follow-Up Studies);基因表达谱(Gene Expression Profiling);基因型(Genotype);人类(Humans);免疫因子类(Immunologic Factors);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);男(雄)性(Male);中年人(Middle Aged);表型(Phenotype);泼尼松(Prednisone);原癌基因蛋白质c-mdm2(Proto-Oncogene Proteins c-mdm2);危险因素(Risk Factors);治疗结果(Treatment Outcome);肿瘤抑制蛋白质p53(Tumor Suppressor Protein p53);长春新碱(Vincristine)
DOI
10.1182/blood-2012-12-473702
PMID
23982177
发布时间
2021-10-21
基金项目
P30 CA016672/CA/NCI NIH HHS/United States
P50CA142509/CA/NCI NIH HHS/United States
P50CA136411/CA/NCI NIH HHS/United States
CA016672/CA/NCI NIH HHS/United States
1R01CA160558/CA/NCI NIH HHS/United States
RC1 CA146299/CA/NCI NIH HHS/United States
1RC1CA146299/CA/NCI NIH HHS/United States
P50 CA136411/CA/NCI NIH HHS/United States
R01 CA138688/CA/NCI NIH HHS/United States
R01CA138688/CA/NCI NIH HHS/United States
R01 CA160558/CA/NCI NIH HHS/United States
P50 CA142509/CA/NCI NIH HHS/United States
- 浏览137
Blood
2630-40页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
